<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Nail-patella syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Nail-patella syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Nail-patella syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Niaudet, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Olivia Gillion Boyer, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tej K Mattoo, MD, DCH, FRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen V Firth, DM, FRCP, FMedSci
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The nail-patella syndrome (NPS,
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.omim.org%2Fentry%2F161200&amp;token=G%2BkOOgscg7PQzd0gXq5S98LRxEirDQev1qznCrLhLon5RapBmAR0vSp3B7Sjn3a8&amp;TOPIC_ID=6116" target="_blank">
          MIM #161200
         </a>
         ) or hereditary osteo-onychodysplasia (HOOD syndrome) is a rare autosomal dominant disorder. It is characterized by limb and pelvic skeletal abnormalities (eg, hypoplastic or absent patella, dysplasia of elbows, including pterygia, and iliac horns), nail and distal digital abnormalities, and kidney disease.
        </p>
        <p>
         The clinical manifestations, diagnosis, and management of children with NPS will be reviewed here.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          INCIDENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The estimated incidence of NPS is 1 per 50,000 [
         <a href="#rid1">
          1,2
         </a>
         ]. The disease has been reported in patients all around the world.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOGENESIS AND LMX1B GENE MUTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         NPS is an autosomal dominant disorder with full gene penetrance but variability of expression even within families [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
         Approximately 85 percent of families with NPS present with mutations of the
         <em>
          LMX1B
         </em>
         gene located at the distal end of the long arm of chromosome 9 [
         <a href="#rid5">
          5-7
         </a>
         ]. LMX1B is a transcription factor of the LIM-homeodomain type that plays an important role for limb and kidney development in vertebrates; however, it is expressed lifelong within the podocyte and it is essential for the maintenance the structured actin cytoskeleton in podocytes [
         <a href="#rid8">
          8
         </a>
         ]. More than 180 heterozygous mutations in
         <em>
          LMX1B
         </em>
         have been reported, including missense, splicing, deletions, and nonsense mutations [
         <a href="#rid9">
          9
         </a>
         ]. Most mutations result in protein truncation [
         <a href="#rid3">
          3,7,10-12
         </a>
         ]. The identification of entire
         <em>
          LMX1B
         </em>
         deletions confirms that haploinsufficiency is the principal pathogenetic mechanism of NPS [
         <a href="#rid13">
          13
         </a>
         ]. Studies in homozygous knock-out mice and in vitro assays demonstrated that LMX1B protein expressed in glomerular podocytes helps control the transcription of multiple genes integral for proper glomerular basement membrane (GBM) formation, and/or glomerular podocyte differentiation and function during the early stages of kidney development [
         <a href="#rid5">
          5,14-17
         </a>
         ]. Putative target genes include
         <em>
          COL4A3
         </em>
         and
         <em>
          COLA4
         </em>
         , genes for alpha-4 chains of collagen type IV [
         <a href="#rid14">
          14,15
         </a>
         ], and
         <em>
          NPHS2
         </em>
         and
         <em>
          CD2AP
         </em>
         genes, which encode podocyte proteins [
         <a href="#rid15">
          15,16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6093.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)"
         </a>
         .)
        </p>
        <p>
         In addition, there are case reports of
         <em>
          LMX1B
         </em>
         mutation (R246 or R249 missense mutations) associated with familial focal segmental glomerulosclerosis (FSGS), but without any other clinical features of NPS [
         <a href="#rid18">
          18-20
         </a>
         ]. A heterozygous
         <em>
          A278V
         </em>
         mutation was also reported in a child with steroid-resistant nephrotic syndrome and a lack of ossification of the proximal radial epiphysis but without nail or other bone anomalies associated with NPS [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/117559.html" rel="external">
          "Focal segmental glomerulosclerosis: Genetic causes"
         </a>
         .)
        </p>
        <p>
         A study of 55 families with NPS reported that
         <em>
          LMX1B
         </em>
         mutations were not found in 9 percent of the families, suggesting that mutation in other genes may be involved [
         <a href="#rid22">
          22
         </a>
         ]. A loss-of-function mutation in
         <em>
          WIF1
         </em>
         , which is involved in mesoderm segmentation, was identified in a family with a dominantly inherited nail-patella-like disorder who tested negative for
         <em>
          LMX1B
         </em>
         mutation [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2753322">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         NPS is classically characterized by limb and pelvic skeletal abnormalities (eg, hypoplastic or absent patella, dysplasia of elbows and iliac horns), nail and distal digital abnormalities, and kidney disease. However, information from two large cases series demonstrated additional clinical manifestations including sensorineural hearing loss and ophthalmological disease [
         <a href="#rid3">
          3,4
         </a>
         ]. Data were obtained from comprehensive evaluation of 126 patients from 44 families recruited from genetic departments in Great Britain [
         <a href="#rid4">
          4
         </a>
         ], and 106 patients from 22 unrelated families and 10 sporadic subjects [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The following clinical manifestations of NPS and relative frequency for the major findings are based on the results from these two large cohorts [
         <a href="#rid3">
          3,4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nail and distal digital abnormalities (100 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Limb and pelvic abnormalities (almost 100 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney disease (30 to 40 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other findings:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sensorineural hearing loss
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ophthalmologic disease (eg, glaucoma)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Gastrointestinal involvement
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vasomotor problems
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other neurologic and orthopedic manifestations
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2753449">
         <span class="h2">
          Nail and digital abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Almost all patients with NPS have nail and/or distal digital abnormalities [
         <a href="#rid3">
          3,4
         </a>
         ]. These findings are typically bilateral and symmetrical, and may be observed at birth [
         <a href="#rid3">
          3,4
         </a>
         ]. Toenails are usually less frequently involved than fingernails and have less severe abnormalities. If the toenails are involved, it is often the little toenail that is most affected. Thumbnails are the most severely affected of the fingernails and the severity tends to decrease towards the little finger (
         <a class="graphic graphic_picture graphicRef98100" href="/z/d/graphic/98100.html" rel="external">
          picture 1
         </a>
         ). For each individual fingernail, the ulnar side is more severely affected.
        </p>
        <p>
         The following nail and distal digital changes are observed in NPS [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nail hypoplasia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nail dystrophic changes, including discoloration, abnormal ridging and splitting, and triangular lunulae, a pathognomic finding (
         <a class="graphic graphic_picture graphicRef98561" href="/z/d/graphic/98561.html" rel="external">
          picture 2
         </a>
         ). The lunula is the visible root of the nail that normally is a crescent-shaped, whitish area at the nail bed, rather than the triangular shape (apex away from the base) observed in close to 80 to 90 percent of patients with NPS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Distal digital changes are observed in almost all patients. The most common finding is the loss of the creases in the skin overlying the distal interphalangeal joint (
         <a class="graphic graphic_picture graphicRef98563" href="/z/d/graphic/98563.html" rel="external">
          picture 3
         </a>
         ). Other findings include flexion and hyperextension abnormalities of the proximal and distal interphalangeal joints, and swan-neck abnormalities of the fingers (
         <a class="graphic graphic_picture graphicRef98100" href="/z/d/graphic/98100.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef55390" href="/z/d/graphic/55390.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2753328">
         <span class="h2">
          Limb and pelvic abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limb and pelvic abnormalities are observed in almost all patients. They include [
         <a href="#rid3">
          3,4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patellar abnormalities – Almost all patients have either patellar aplasia (
         <a class="graphic graphic_diagnosticimage graphicRef98562" href="/z/d/graphic/98562.html" rel="external">
          image 1
         </a>
         ) or hypoplasia, which may be asymmetrical [
         <a href="#rid24">
          24
         </a>
         ]. In patients with patellar hypoplasia, recurrent subluxation or dislocation of the patella causes lateral slippage during knee flexion [
         <a href="#rid4">
          4,25,26
         </a>
         ]. In one large case series of 124 patients, three-quarters of the cohort reported knee symptoms including pain, knee instability, locking of the knee, inability to straighten the knee joint, and patellar dislocation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elbow abnormalities – Almost all patients with NPS have elbow abnormalities, including posterior subluxation of the radial head, hypoplasia of the lateral epicondyle and capitellum, and prominence of the medial epicondyle. Elbow abnormalities may be asymmetrical. Symptoms and findings due to these deformities include pain, limited elbow extension, limited pronation and supination, cubitus valgus (increased carrying angle of the arm), and pterygia (webbing of the elbow).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leg and arm abnormalities – Almost all patients exhibit underdevelopment of arm and leg proximal musculature and hyperextensibility of large joints (eg, hip).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Iliac horns are bilateral symmetrical bone formations arising from the antero-superior iliac crest that project posteriorly and laterally (
         <a class="graphic graphic_diagnosticimage graphicRef98098" href="/z/d/graphic/98098.html" rel="external">
          image 2
         </a>
         ). Iliac horns are pathognomonic asymptomatic radiologic features of NPS, and are present in 70 to 80 percent of patients. Large horns may be detected by palpation on clinical examination. Iliac horns may also be detected by prenatal ultrasound [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ankle and feet abnormalities – Ankle and feet deformities include talipes equinovarus (clubfoot), calcaneovalgus (hyperdorsiflexion of the foot with abduction of the forefoot), pes planus (flat foot), and tight Achilles tendon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adults with NPS have a bone-mineral density that is 8 to 20 percent lower than controls, which is associated with an increase in the prevalence of fractures and scoliosis [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Orthopedic surgeons most experienced with NPS generally discourage any attempts at orthopedic "repair" of limb and pelvic abnormalities due to the profound defect in the baseline structures. When an orthopedic intervention is planned, it is important to determine if there are any abnormal bone or soft tissue abnormalities that could be affected by the procedure. For example, in patients with elbow pterygia, the neurovascular bundle may be superficial and within the confines of the webbing [
         <a href="#rid4">
          4
         </a>
         ]. In addition, patients with NPS often have abnormal joint anatomy, which is important to determine prior to surgical intervention so that the appropriate intervention can be used [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Kidney manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kidney disease (30 to 40 percent) varies among affected families and within single families [
         <a href="#rid3">
          3,4
         </a>
         ]. Because the underlying pathology is a defect in the glomerular basement membrane (GBM), patients with kidney involvement initially present with microalbuminuria and proteinuria. Proteinuria may present at any age or be intermittent, and is more prevalent during pregnancy. Microscopic hematuria is also common.
        </p>
        <p>
         Although there are no longitudinal data that provide information on the long-term kidney prognosis, there is limited evidence that patients with NPS have an accelerated loss of kidney function that is twice the normal rate of deterioration in unaffected individuals [
         <a href="#rid30">
          30
         </a>
         ]. Some patients with proteinuria will develop nephrotic syndrome and infrequently (1 to 5 percent of all patients) progress to kidney failure (KF) [
         <a href="#rid3">
          3,4
         </a>
         ]. Impairment of kidney function, and in a small minority of patients, KF, is thought to be due to progressive thickening and disorganization of the GBM. Patients with chronic and/or end-stage kidney disease are reported to have
         <em>
          LMXIB
         </em>
         mutations mainly located to a short region of the
         <em>
          LMX1B
         </em>
         homeodomain and to the N-terminal region of the
         <em>
          LIM
         </em>
         domain [
         <a href="#rid31">
          31
         </a>
         ]. In addition, specific
         <em>
          LMX1B
         </em>
         mutations (p.R246P, p.R246Q, p.R249Q missense mutation) have been associated with familial focal segmental glomerulosclerosis (FSGS), but without any other clinical features of NPS [
         <a href="#rid18">
          18,20
         </a>
         ]. (See
         <a class="local">
          'Pathogenesis and LMX1B gene mutations'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Histopathologic findings from kidney biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         NPS is distinguished from other diseases associated with proteinuria by the electron microscopic pathognomic finding of irregular and lucent rarefactions containing clusters of cross-banded collagen fibrils within the lamina densa of the GBM (
         <a class="graphic graphic_diagnosticimage graphicRef131222" href="/z/d/graphic/131222.html" rel="external">
          image 3
         </a>
         ) [
         <a href="#rid32">
          32-35
         </a>
         ]. These abnormalities may also be found in the mesangial matrix, but the tubular basement membranes are not affected. The clusters of fibrils are clearly demonstrated by staining with uranyl acetate and phosphotungstic acid. They may be observed within segments of thickened GBM or along the entire GBM. Although the collagen fibrils are a constant feature of NPS, they are also found in patients without clinical evidence of kidney involvement [
         <a href="#rid36">
          36
         </a>
         ]. Other lesions such as podocyte myelin figures and zebra bodies observed in patients with p.R246Q
         <em>
          LMX1B
         </em>
         mutation are most commonly associated with Fabry disease (see
         <a class="medical medical_review" href="/z/d/html/115165.html" rel="external">
          "Fabry disease: Kidney manifestations", section on 'Pathology'
         </a>
         ), and may lead to misdiagnosis [
         <a href="#rid37">
          37
         </a>
         ]. Furthermore, there is no correlation between the severity of the ultrastructural lesions at diagnosis and the clinical kidney manifestations [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         In contrast, light microscopy and immunofluorescence microscopy are normal or demonstrate nonspecific changes. In patients with heavy proteinuria and/or impaired kidney function, light microscopy may show GBM thickening and nonspecific lesions of FSGS (
         <a class="graphic graphic_diagnosticimage graphicRef131221" href="/z/d/graphic/131221.html" rel="external">
          image 4
         </a>
         ), and immunofluorescence microscopy may show nonspecific segmental deposits of immunoglobulin M (IgM) and complement component 3 (C3) in the sclerotic areas.
        </p>
        <p class="headingAnchor" id="H2754803">
         <span class="h2">
          Other findings
         </span>
        </p>
        <p class="headingAnchor" id="H2754810">
         <span class="h3">
          Sensorineural hearing loss
         </span>
         <span class="headingEndMark">
          —
         </span>
         In one case series of 106 patients, sensorineural hearing loss was observed in 11 of 24 patients from four of six families who underwent audiometric testing [
         <a href="#rid3">
          3
         </a>
         ]. As a result, the overall prevalence of hearing loss is unclear. In this study, bilateral involvement was observed in one-third of the cases with hearing impairment. The mean age of detection was 46.7 years (range 17.5 to 69.2 years). Unaffected family members had normal hearing.
        </p>
        <p class="headingAnchor" id="H2754838">
         <span class="h3">
          Ophthalmological disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both open-angle glaucoma and ocular hypertension have been observed in patients with NPS [
         <a href="#rid3">
          3,4,38
         </a>
         ]. However, there is considerable variability in the reported prevalence of these two disorders from 16 to 35 percent [
         <a href="#rid3">
          3,4
         </a>
         ]. Approximately half of affected patients have hyperpigmentation of the central part of the iris, called Lester's sign [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2754913">
         <span class="h3">
          Gastrointestinal involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         In one case series, one-third of patients reported gastrointestinal symptoms that included symptoms of irritable bowel syndrome (characterized by alternating constipation and diarrhea accompanied with cramping abdominal pain) and constipation requiring intervention [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2754935">
         <span class="h3">
          Vasomotor symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         In one case series, 12 of 22 patients who were queried reported symptoms related to poor peripheral circulation (cold hands and feet even in warm weather) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2755834">
         <span class="h3">
          Other orthopedic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         In one study, back pain was reported in half of the cohort, which may be associated with the increased incidence of lumbar lordosis seen in patients with NPS [
         <a href="#rid4">
          4
         </a>
         ]. There was also an increased risk of mild scoliosis, other spinal abnormalities, and pectus excavatum.
        </p>
        <p class="headingAnchor" id="H2755813">
         <span class="h3">
          Other neurologic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reduced sensitivity to pain and temperature in the hands and feet of patients with NPS has been reported [
         <a href="#rid4">
          4
         </a>
         ]. Complaints of intermittent tingling, numbness, and burning without any precipitant have also been elicited. In addition, both attention deficient hyperactivity disorder (ADHD) and mood disorders have been reported to be associated with NPS [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2753162">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical diagnosis of NPS is based on the presence of classical physical and radiologic findings [
         <a href="#rid29">
          29,30
         </a>
         ]. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absent or dystrophic nails including triangular lunulae (a pathognomonic finding) (
         <a class="graphic graphic_picture graphicRef98561" href="/z/d/graphic/98561.html" rel="external">
          picture 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef98100" href="/z/d/graphic/98100.html" rel="external">
          picture 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absent or hypoplastic patella, which may require radiographic confirmation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elbow abnormalities (limitation of extension, pronation, and supination; cubitus valgus; and antecubital pterygia)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Iliac horns, a pathognomonic finding, demonstrated on pelvic radiograph are found in 70 percent of patients (
         <a class="graphic graphic_diagnosticimage graphicRef98098" href="/z/d/graphic/98098.html" rel="external">
          image 2
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Because of the variability in phenotypic expression, genetic testing should be considered in patients in whom a diagnosis of NPS is suspected.
        </p>
        <p class="headingAnchor" id="H2755027">
         <span class="h2">
          Molecular genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         In cases where the diagnosis remains uncertain, molecular genetic testing to detect a mutation of the
         <em>
          LMX1B
         </em>
         gene can be used to confirm the diagnosis. Gene testing for
         <em>
          LMX1B
         </em>
         mutations is commercially available. The National Center for Biotechnology Information (NCBI)
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=ODIqmPyH03K5IrNHL4oottyJV%2BtPhS7Gs3UPQx%2BHe7Xh4E9j4nqEtGCcPjsW%2BwBz&amp;TOPIC_ID=6116" target="_blank">
          Genetic Testing Registry
         </a>
         lists commercial and academic laboratories throughout the world that offer molecular genetic testing for NPS.
        </p>
        <p class="headingAnchor" id="H2755475">
         <span class="h2">
          Kidney biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Renal biopsy is not necessary if the diagnosis is confirmed by genetic testing. There is no clear relationship between the clinical course and renal histopathology [
         <a href="#rid30">
          30
         </a>
         ], and findings on kidney biopsy do not alter the clinical management.
        </p>
        <p class="headingAnchor" id="H2755257">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kidney biopsy is not necessary if the diagnosis is confirmed by genetic testing. There is no clear relationship between the clinical course and kidney histopathology [
         <a href="#rid4">
          4,29
         </a>
         ]. However, NPS is distinguished from these other disorders by the characteristic combination of
         <strong>
          both
         </strong>
         patellar and nail abnormalities. In addition, the pathognomic findings of iliac horns and/or triangular lunulae differentiate NPS from any other condition.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disorders with patellar abnormalities include small patella syndrome (ischiopatellar dysplasia, coxo-podo-patellar syndrome, Scott-Taor syndrome), patella aplasia-hypoplasia, familial recurrent dislocation of the patella, Meier-Gorlin syndrome (absent patella, microtia, short stature, and characteristic facial appearance), genitopatellar syndrome (patellar, genital, and renal abnormalities; microcephaly; and intellectual disability), and RADADILINO syndrome (radial defects, absent or hypoplastic patellae, dislocated joints, short stature, cleft palate, and facial dysmorphism).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disorders with nail abnormalities include DOOR syndrome (nail, digital, renal, and ophthalmological abnormalities; bilateral ptosis; and Dandy-Walker malformation), Trisomy 8 mosaicism, and Senior syndrome (small nails, short stature, characteristic facial appearance, and mild intellectual impairment).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coffin-Siris syndrome has both nail and patellar abnormalities, but is also associated with intellectual disability and coarse facial features.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2755367">
         <span class="h1">
          EVALUATION FOLLOWING INITIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the diagnosis of nail-patella syndrome (NPS) is made, the following evaluation is recommended to determine the extent of the disease [
         <a href="#rid29">
          29
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History and physical examination to detect any orthopedic problems, and identify any gastrointestinal, neurologic, or vasomotor abnormalities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment to detect kidney involvement includes blood pressure measurement, urinalysis, and measurement of a urine protein to creatinine ratio of a sample of urine from the first morning void. (See
         <a class="local">
          'Kidney manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ophthalmological examination to detect glaucoma or ocular hypertension.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2755414">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no specific therapy for NPS. Management is directed towards identifying and treating complications, and involves a multidisciplinary team [
         <a href="#rid3">
          3,4,29
         </a>
         ]. In our practice, we use the following approach:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitoring for the following long-term complications:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Kidney disease − Annual measurement of blood pressure (BP) and urine protein to creatinine ratio on a sample from a first morning void. However, it may be challenging to obtain adequate BP measurement in patients with limb abnormalities.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Eye disease – Ophthalmologic screening every two years that includes measurement of intraocular pressure, examination of the optic disc, and assessment of visual fields.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Orthopedic management includes analgesics, physiotherapy, splinting, bracing, or surgery. If at all possible, orthopedic intervention should only be performed by surgeons who have expertise in treating patients with NPS. Prior to surgery or intensive physiotherapy, identifying any bony or soft tissue abnormality by magnetic resonance imaging that would impact the choice of intervention is recommended.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of glaucoma, hearing loss, and gastrointestinal complaints for patients with NPS is the same as for individuals of the general population with these disorders.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney disease – For patients with nephropathy, our management approach includes the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with documented proteinuria/albuminuria, we provide either angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). This suggestion is based on data that angiotensin antagonism reduces protein excretion and slows kidney disease progression in other nondiabetic, proteinuric, glomerular diseases [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/117983.html" rel="external">
          "Steroid-resistant nephrotic syndrome in children: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Medications that may be detrimental (eg, nonsteroidal antiinflammatory drugs) are avoided.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with kidney failure (KF), kidney transplantation is the preferred renal replacement therapy. NPS does not reoccur after transplantation and patients do not develop antibodies to glomerular basement membrane (GBM) proteins, as is seen in patient with hereditary nephritis (Alport syndrome). (See
         <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">
          "Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic counseling should be provided to all affected families. Families should be informed that NPS is an autosomal dominant disorder with variability of expression even within families.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and pathogenesis
         </strong>
         – The nail-patella syndrome (NPS), or osteo-onychodysplasia, is an autosomal dominant disorder characterized by hypoplastic or absent patella, dystrophic fingernails and toenails, and dysplasia of elbows and iliac horns. NPS is due to mutations of the
         <em>
          LMX1B
         </em>
         gene, a transcription factor of the LIM-homeodomain type that plays an important role for limb and kidney development. (See
         <a class="local">
          'Pathogenesis and LMX1B gene mutations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Manifestations
         </strong>
         – The major clinical manifestations and their relative frequency of NPS include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nail and distal digital abnormalities (100 percent) include nail hypoplasia (
         <a class="graphic graphic_picture graphicRef98100" href="/z/d/graphic/98100.html" rel="external">
          picture 1
         </a>
         ) and dystropic changes (discoloration, abnormal ridging and splitting, and triangular lunulae [pathognomic finding] (
         <a class="graphic graphic_picture graphicRef98561" href="/z/d/graphic/98561.html" rel="external">
          picture 2
         </a>
         )), and distal digital changes include loss of the creases in the skin overlying the distal interphalangeal joint (
         <a class="graphic graphic_picture graphicRef98563" href="/z/d/graphic/98563.html" rel="external">
          picture 3
         </a>
         ), and flexion and extension abnormalities. (See
         <a class="local">
          'Nail and digital abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Limb and pelvic abnormalities (100 percent) include patellar aplasia or hypoplasia (
         <a class="graphic graphic_diagnosticimage graphicRef98562" href="/z/d/graphic/98562.html" rel="external">
          image 1
         </a>
         ), elbow abnormalities, and the pathognomic finding of iliac horns (80 percent) (
         <a class="graphic graphic_diagnosticimage graphicRef98098" href="/z/d/graphic/98098.html" rel="external">
          image 2
         </a>
         ). (See
         <a class="local">
          'Limb and pelvic abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Kidney disease (30 to 40 percent) initially presents with microalbuminuria and proteinuria. Some patients will progress to nephrosis and infrequently (1 to 5 percent of all patients) to kidney failure (KF). (See
         <a class="local">
          'Kidney manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other manifestations include sensorineural hearing loss, ophthalmological disease (ie, glaucoma, and intraocular hypertension), gastrointestinal complaints, back pain, and vasomotor and distal neurological symptoms. (See
         <a class="local">
          'Other findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The clinical diagnosis of NPS is based on the presence of classical physical and radiologic findings. These include nail abnormalities (eg, triangular lunulae), patellar hypoplasia or aplasia, elbow abnormalities, and the radiologic finding of iliac horns. In cases where the diagnosis remains uncertain, molecular genetic testing to detect a mutation of the
         <em>
          LMX1B
         </em>
         gene is usually used to confirm the diagnosis. Kidney biopsy is not warranted, as it is not typically needed to make the diagnosis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessing extent of disease
         </strong>
         – Once the diagnosis of NPS is made, evaluation is recommended to determine the extent of the disease. This entails a comprehensive history and physical examination to detect orthopedic, gastrointestinal, neurologic, or vasomotor abnormalities; and screening for kidney and ophthalmologic disease. (See
         <a class="local">
          'Evaluation following initial diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – There is no specific therapy for NPS. Management is directed towards identifying and treating complications. We suggest the following management approach for patients with NPS (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Monitoring for the development of kidney disease (annual measurement of blood pressure and urine protein to creatinine ratio from a first morning void), and ophthalmologic screening every two years.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Orthopedic management consists of analgesics, physiotherapy, splinting, bracing, or surgery based on the specific condition.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Management of glaucoma, hearing loss, and gastrointestinal complaints for patients with NPS is the same as for individuals of the general population with these disorders.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with nephropathy, we provide either angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy to decrease protein excretion rate and to slow the progression of kidney disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with KF, we recommend kidney transplantation as the preferred renal replacement therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). NPS does not recur after transplantation and there have been no reports of antibodies to glomerular basement membrane (GBM) proteins following transplantation.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Dombros N, Katz A. Nail patella-like renal lesions in the absence of skeletal abnormalities. Am J Kidney Dis 1982; 1:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int 2000; 58:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bongers EM, Huysmans FT, Levtchenko E, et al. Genotype-phenotype studies in nail-patella syndrome show that LMX1B mutation location is involved in the risk of developing nephropathy. Eur J Hum Genet 2005; 13:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sweeney E, Fryer A, Mountford R, et al. Nail patella syndrome: a review of the phenotype aided by developmental biology. J Med Genet 2003; 40:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen H, Lun Y, Ovchinnikov D, et al. Limb and kidney defects in Lmx1b mutant mice suggest an involvement of LMX1B in human nail patella syndrome. Nat Genet 1998; 19:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vollrath D, Jaramillo-Babb VL, Clough MV, et al. Loss-of-function mutations in the LIM-homeodomain gene, LMX1B, in nail-patella syndrome. Hum Mol Genet 1998; 7:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamlington JD, Jones C, McIntosh I. Twenty-two novel LMX1B mutations identified in nail patella syndrome (NPS) patients. Hum Mutat 2001; 18:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burghardt T, Kastner J, Suleiman H, et al. LMX1B is essential for the maintenance of differentiated podocytes in adult kidneys. J Am Soc Nephrol 2013; 24:1830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harita Y, Kitanaka S, Isojima T, et al. Spectrum of LMX1B mutations: from nail-patella syndrome to isolated nephropathy. Pediatr Nephrol 2017; 32:1845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dreyer SD, Zhou G, Baldini A, et al. Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome. Nat Genet 1998; 19:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knoers NV, Bongers EM, van Beersum SE, et al. Nail-patella syndrome: identification of mutations in the LMX1B gene in Dutch families. J Am Soc Nephrol 2000; 11:1762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntosh I, Dreyer SD, Clough MV, et al. Mutation analysis of LMX1B gene in nail-patella syndrome patients. Am J Hum Genet 1998; 63:1651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bongers EM, de Wijs IJ, Marcelis C, et al. Identification of entire LMX1B gene deletions in nail patella syndrome: evidence for haploinsufficiency as the main pathogenic mechanism underlying dominant inheritance in man. Eur J Hum Genet 2008; 16:1240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morello R, Zhou G, Dreyer SD, et al. Regulation of glomerular basement membrane collagen expression by LMX1B contributes to renal disease in nail patella syndrome. Nat Genet 2001; 27:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miner JH, Morello R, Andrews KL, et al. Transcriptional induction of slit diaphragm genes by Lmx1b is required in podocyte differentiation. J Clin Invest 2002; 109:1065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rohr C, Prestel J, Heidet L, et al. The LIM-homeodomain transcription factor Lmx1b plays a crucial role in podocytes. J Clin Invest 2002; 109:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunston JA, Hamlington JD, Zaveri J, et al. The human LMX1B gene: transcription unit, promoter, and pathogenic mutations. Genomics 2004; 84:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyer O, Woerner S, Yang F, et al. LMX1B mutations cause hereditary FSGS without extrarenal involvement. J Am Soc Nephrol 2013; 24:1216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isojima T, Harita Y, Furuyama M, et al. LMX1B mutation with residual transcriptional activity as a cause of isolated glomerulopathy. Nephrol Dial Transplant 2014; 29:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards N, Rice SJ, Raman S, et al. A novel LMX1B mutation in a family with end-stage renal disease of 'unknown cause'. Clin Kidney J 2015; 8:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giglio S, Provenzano A, Mazzinghi B, et al. Heterogeneous genetic alterations in sporadic nephrotic syndrome associate with resistance to immunosuppression. J Am Soc Nephrol 2015; 26:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghoumid J, Petit F, Holder-Espinasse M, et al. Nail-Patella Syndrome: clinical and molecular data in 55 families raising the hypothesis of a genetic heterogeneity. Eur J Hum Genet 2016; 24:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones MC, Topol SE, Rueda M, et al. Mutation of WIF1: a potential novel cause of a Nail-Patella-like disorder. Genet Med 2017; 19:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tigchelaar S, Rooy Jd, Hannink G, et al. Radiological characteristics of the knee joint in nail patella syndrome. Bone Joint J 2016; 98-B:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guidera KJ, Satterwhite Y, Ogden JA, et al. Nail patella syndrome: a review of 44 orthopaedic patients. J Pediatr Orthop 1991; 11:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lippacher S, Mueller-Rossberg E, Reichel H, Nelitz M. Correction of malformative patellar instability in patients with nail-patella syndrome: a case report and review of the literature. Orthop Traumatol Surg Res 2013; 99:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feingold M, Itzchak Y, Goodman RM. Ultrasound prenatal diagnosis of the Nail-Patella syndrome. Prenat Diagn 1998; 18:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Towers AL, Clay CA, Sereika SM, et al. Skeletal integrity in patients with nail patella syndrome. J Clin Endocrinol Metab 2005; 90:1961.
          </a>
         </li>
         <li class="breakAll">
          National Center for Biotechnology Information (NCBI) Gene Reviews. Nail-Patella syndrome. www.ncbi.nlm.nih.gov/books/NBK1132/#nail-ps.Resources (Accessed on October 23, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemley KV. Kidney disease in nail-patella syndrome. Pediatr Nephrol 2009; 24:2345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harita Y, Urae S, Akashio R, et al. Clinical and genetic characterization of nephropathy in patients with nail-patella syndrome. Eur J Hum Genet 2020; 28:1414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Del Pozo E, Lapp H. Ultrastructure of the kidney in the nephropathy of the nail--patella syndrome. Am J Clin Pathol 1970; 54:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoyer JR, Michael AF, Vernier RL. Renal disease in nail-patella syndrome: clinical and morphologic studies. Kidney Int 1972; 2:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabnis SG, Antonovych TT, Argy WP, et al. Nail-patella syndrome. Clin Nephrol 1980; 14:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morita T, Laughlin LO, Kawano K, et al. Nail-Patella syndrome. Light and electron microscopic studies of the kidney. Arch Intern Med 1973; 131:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett WM, Musgrave JE, Campbell RA, et al. The nephropathy of the nail-patella syndrome. Clinicopathologic analysis of 11 kindred. Am J Med 1973; 54:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lei L, Oh G, Sutherland S, et al. Myelin bodies in LMX1B-associated nephropathy: potential for misdiagnosis. Pediatr Nephrol 2020; 35:1647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romero P, Sanhueza F, Lopez P, et al. c.194 A&gt;C (Q65P) mutation in the LMX1B gene in patients with nail-patella syndrome associated with glaucoma. Mol Vis 2011; 17:1929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witzgall R. Nail-patella syndrome. Pflugers Arch 2017; 469:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López-Arvizu C, Sparrow EP, Strube MJ, et al. Increased symptoms of attention deficit hyperactivity disorder and major depressive disorder symptoms in Nail-patella syndrome: potential association with LMX1B loss-of-function. Am J Med Genet B Neuropsychiatr Genet 2011; 156B:59.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6116 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7158631" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Nail patella-like renal lesions in the absence of skeletal abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10972657" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Estimating prevalence in single-gene kidney diseases progressing to renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15928687" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Genotype-phenotype studies in nail-patella syndrome show that LMX1B mutation location is involved in the risk of developing nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12624132" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Nail patella syndrome: a review of the phenotype aided by developmental biology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9590288" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Limb and kidney defects in Lmx1b mutant mice suggest an involvement of LMX1B in human nail patella syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9618165" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Loss-of-function mutations in the LIM-homeodomain gene, LMX1B, in nail-patella syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11668639" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Twenty-two novel LMX1B mutations identified in nail patella syndrome (NPS) patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23990680" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : LMX1B is essential for the maintenance of differentiated podocytes in adult kidneys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27450397" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Spectrum of LMX1B mutations: from nail-patella syndrome to isolated nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9590287" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10966502" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Nail-patella syndrome: identification of mutations in the LMX1B gene in Dutch families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9837817" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Mutation analysis of LMX1B gene in nail-patella syndrome patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18414507" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Identification of entire LMX1B gene deletions in nail patella syndrome: evidence for haploinsufficiency as the main pathogenic mechanism underlying dominant inheritance in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11175791" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Regulation of glomerular basement membrane collagen expression by LMX1B contributes to renal disease in nail patella syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11956244" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Transcriptional induction of slit diaphragm genes by Lmx1b is required in podocyte differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11956245" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The LIM-homeodomain transcription factor Lmx1b plays a crucial role in podocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15498463" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The human LMX1B gene: transcription unit, promoter, and pathogenic mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23687361" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : LMX1B mutations cause hereditary FSGS without extrarenal involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24042019" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : LMX1B mutation with residual transcriptional activity as a cause of isolated glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25713721" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A novel LMX1B mutation in a family with end-stage renal disease of 'unknown cause'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25060053" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Heterogeneous genetic alterations in sporadic nephrotic syndrome associate with resistance to immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25898926" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Nail-Patella Syndrome: clinical and molecular data in 55 families raising the hypothesis of a genetic heterogeneity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28383544" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Mutation of WIF1: a potential novel cause of a Nail-Patella-like disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27037430" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Radiological characteristics of the knee joint in nail patella syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1960197" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Nail patella syndrome: a review of 44 orthopaedic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24029584" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Correction of malformative patellar instability in patients with nail-patella syndrome: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9742578" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Ultrasound prenatal diagnosis of the Nail-Patella syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15623820" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Skeletal integrity in patients with nail patella syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15623820" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Skeletal integrity in patients with nail patella syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18535845" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Kidney disease in nail-patella syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32457516" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Clinical and genetic characterization of nephropathy in patients with nail-patella syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5484038" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Ultrastructure of the kidney in the nephropathy of the nail--patella syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4571998" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Renal disease in nail-patella syndrome: clinical and morphologic studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7418282" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Nail-patella syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4682988" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Nail-Patella syndrome. Light and electron microscopic studies of the kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4569963" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The nephropathy of the nail-patella syndrome. Clinicopathologic analysis of 11 kindred.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32356190" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Myelin bodies in LMX1B-associated nephropathy: potential for misdiagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21850167" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : c.194 A&gt;C (Q65P) mutation in the LMX1B gene in patients with nail-patella syndrome associated with glaucoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28681095" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Nail-patella syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21184584" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Increased symptoms of attention deficit hyperactivity disorder and major depressive disorder symptoms in Nail-patella syndrome: potential association with LMX1B loss-of-function.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
